Agenus (AGEN) Misleading Statements Case

D. Massachusetts

Court

1:24-CV-12299

Case number

23 Jan 2023

Class period Start

17 Jul 2024

Class period End

08 Nov 2024

Lead Plaintiff motion deadline

$AGEN stockholders filed a claim against Agenus for misleading them about the potential success of its cancer immunotherapy trials.
After the FDA meeting results on July 18, 2024, $AGEN dropped by 58.83%.
Agenus investors can join this case to be notified about potential recovery.
Case Details:

On January 23, 2023, Agenus issued statements announcing positive data from its botensilimab and balstilimab combination therapy trials for colorectal cancer, leading investors to believe the treatment had strong potential for FDA approval and commercial success.

However, on July 18, 2024, Agenus announced the results of an FDA meeting in which the agency advised against pursuing accelerated approval of the therapy due to concerns that the trial’s results may not translate into a survival benefit. Following this announcement, Agenus' stock dropped by 58.83%, causing significant losses for investors who had relied on the company's optimistic forecasts.

Based on these events, an investor filed a lawsuit against Agenus, alleging:
The company misrepresented the potential success of its immunotherapy drug.
Agenus failed to disclose critical information regarding the challenges faced during the trial.
These misstatements caused investors to suffer financial losses when the truth was revealed.
A group of investors has already filed a class action suit in the District Court of Massachusetts.

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Fraud,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

18 July 2024

Filing date

06 September 2024

Lead Plaintiff Deadline

08 November 2024

Judge

Hon. Angel Kelley

Agenus (AGEN) Misleading Statements Case

Collecting participants…